PE20151296A1 - Agentes para tratar enfermedades geneticas derivadas de mutaciones sin sentido y metodos para identificarlas - Google Patents

Agentes para tratar enfermedades geneticas derivadas de mutaciones sin sentido y metodos para identificarlas

Info

Publication number
PE20151296A1
PE20151296A1 PE2015001190A PE2015001190A PE20151296A1 PE 20151296 A1 PE20151296 A1 PE 20151296A1 PE 2015001190 A PE2015001190 A PE 2015001190A PE 2015001190 A PE2015001190 A PE 2015001190A PE 20151296 A1 PE20151296 A1 PE 20151296A1
Authority
PE
Peru
Prior art keywords
neurodetic
methods
identify
genetic diseases
agents
Prior art date
Application number
PE2015001190A
Other languages
English (en)
Inventor
Rina Rosin-Arbesfeld
Michal Caspi
Dalia Megiddo
Original Assignee
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49956287&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20151296(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Ramot filed Critical Univ Ramot
Publication of PE20151296A1 publication Critical patent/PE20151296A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics

Abstract

SE REFIERE A METODOS PARA IDENTIFICAR AGENTES CAPACES DE INDUCIR LA TRANSLECTURA DE LAS MUTACIONES SIN SENTIDO QUE PROVOCAN LA FORMACION DE CODONES DE TERMINACION PREMATUROS, UTILES EN EL TRATAMIENTO DE LAS ENFERMEDADES GENETICAS NEURODEGENERATIVAS O DEL NEURODESARROLLO ASOCIADA CON UNA MUTACION SIN SENTIDO, TALES COMO ATROFIA MUSCULAR ESPINAL, ATAXIA-TELANGIECTASIA, SINDROME DE RETT, SINDROME DE USHER, ENTRE OTROS. EN UNA MODALIDAD, LOS AGENTES CAPACES DE INDUCIR LA TRANSLECTURA DE LAS MUTACIONES SIN SENTIDO SON MACROLIDOS ANTIBIOTICOS. TAMBIEN SE REFIERE A COMPOSICIONES QUE COMPRENDEN AL MENOS UN MACROLIDO ANTIBIOTICO, SELECCIONADO PREFERENTEMENTE ENTRE ERITROMICINA, AZITROMICINA Y CLARITROMICINA, O CUALQUIER COMBINACION DE AL MENOS DOS DE DICHOS MACROLIDOS. DICHAS COMPOSICIONES SE ADMINISTRAN PREFERENTEMENTE POR VIA INTRATECAL, INTRANEURAL, INTRACEREBRAL, INTRAVENTRICULAR E INTRACRANEAL
PE2015001190A 2012-12-24 2013-12-24 Agentes para tratar enfermedades geneticas derivadas de mutaciones sin sentido y metodos para identificarlas PE20151296A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261745651P 2012-12-24 2012-12-24
US201361762900P 2013-02-10 2013-02-10

Publications (1)

Publication Number Publication Date
PE20151296A1 true PE20151296A1 (es) 2015-10-15

Family

ID=49956287

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001190A PE20151296A1 (es) 2012-12-24 2013-12-24 Agentes para tratar enfermedades geneticas derivadas de mutaciones sin sentido y metodos para identificarlas

Country Status (16)

Country Link
US (1) US10987370B2 (es)
EP (1) EP2934548A2 (es)
JP (1) JP2016503051A (es)
KR (1) KR20150098675A (es)
AU (1) AU2013368805A1 (es)
BR (1) BR112015015075A2 (es)
CA (1) CA2894992A1 (es)
CL (1) CL2015001814A1 (es)
CR (1) CR20150381A (es)
EA (1) EA201500699A1 (es)
IL (1) IL239467A0 (es)
MD (1) MD20150056A2 (es)
MX (1) MX2015008146A (es)
PE (1) PE20151296A1 (es)
SG (1) SG11201504933WA (es)
WO (1) WO2014102778A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013368805A1 (en) 2012-12-24 2015-08-13 Ramot At Tel-Aviv University Ltd. Agents for treating genetic diseases resulting from nonsense mutations, and methods for identifying the same
WO2015192198A1 (en) * 2014-06-19 2015-12-23 The Hospital For Sick Children Treatment of peroxisome biogenesis disorder
WO2015198329A1 (en) 2014-06-25 2015-12-30 Bio Blast Pharma Ltd. Injectable formulations for intrathecal administration of antibiotic agents
WO2017010382A1 (ja) * 2015-07-14 2017-01-19 国立大学法人大阪大学 筋強直性ジストロフィー治療薬
EP3377073A4 (en) 2015-11-16 2019-06-26 Ohio State Innovation Foundation METHOD AND COMPOSITIONS FOR TREATING DISORDERS AND DISEASES WITH THE SURVIVAL MOTOR NEURON (SMN) PROTEIN
US11213537B2 (en) 2017-09-18 2022-01-04 Friedrich Miescher Institute For Biomedical Research Inhibition of autism spectrum disorder using ribosomal read-through compounds
WO2023235380A1 (en) * 2022-06-01 2023-12-07 Zikani Therapeutics, Inc. Macrolides for treating genetic diseases

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
SI8110592A8 (en) 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
IT1176332B (it) 1984-06-27 1987-08-18 Erba Farmitalia Procedimento per al preparazione di peptidi
CA2127578A1 (en) 1993-07-08 1995-01-09 Keiichi Ajito 16-membered macrolide derivatives and process for producing the same
AP1060A (en) 1998-01-02 2002-04-23 Pfizer Prod Inc Novel erythromycin derivatives.
OA11945A (en) 1999-05-24 2006-04-13 Pfizer Prod Inc 13-Methyl erythromycin derivatives.
US6458538B1 (en) 1999-12-14 2002-10-01 Ptc Therapeutics, Inc. Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
US6455680B1 (en) 2000-12-21 2002-09-24 Abbott Laboratories Methods utilizing aryl thioimines in synthesis of erythromycin derivatives
US20030013692A1 (en) 2001-01-19 2003-01-16 Gullans Steven R. Methods of treating neurological disorders
WO2003099217A2 (en) * 2002-05-23 2003-12-04 Activbiotics, Inc. Methods of treating bacterial infections and diseases associated therewith
WO2004001010A2 (en) 2002-06-21 2003-12-31 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US7786151B2 (en) * 2004-01-09 2010-08-31 Kinopharma, Inc. Therapeutic composition of treating abnormal splicing caused by the excessive kinase induction
US20070072815A1 (en) * 2004-05-04 2007-03-29 Kmiec Eric B Methods and kits to increase the efficiency of oligonucleotide-directed nucleic acid sequence alteration
WO2005118610A2 (en) * 2004-06-01 2005-12-15 Rib-X Pharmaceuticals, Inc. Macrocyclic compounds and methods of making and using the same
EP2514748B1 (en) * 2004-06-08 2016-08-10 Families of Spinal Muscular Atrophy 2,4-diaminoquinazolines for spinal muscular atrophy
US20060018921A1 (en) * 2004-07-16 2006-01-26 Baylor College Of Medicine Histone deacetylase inhibitors and cognitive applications
JP2008527002A (ja) * 2005-01-13 2008-07-24 サートリス ファーマシューティカルズ， インコーポレイテッド 神経変性障害および血液凝固障害を予防および処置するための新規組成物
WO2007022076A2 (en) 2005-08-13 2007-02-22 The Uab Research Foundation Prevention of neurodegeneration by macrolide antibiotics
NZ542111A (en) 2005-08-30 2008-04-30 Otago Innovation Ltd Novel assay
GB0523040D0 (en) * 2005-11-11 2005-12-21 Cyclacel Ltd Combination
US8110681B2 (en) * 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
WO2007144876A1 (en) 2006-06-12 2007-12-21 Ramot At Tel-Aviv University Ltd. Methods for treating cancer
NZ575198A (en) * 2006-08-01 2012-05-25 Families Of Spinal Muscular Atrophy 2,4-diaminoquinazolines for spinal muscular atrophy
US20100234402A1 (en) * 2007-05-31 2010-09-16 Gideon Dreyfuss Methods and compositions for treating spinal muscular atrophy
JP2008307007A (ja) * 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
CA2699039A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of bpp-b as a therapeutic agent
US8008344B2 (en) * 2007-09-14 2011-08-30 NatureWise Biotech and Medicals Corporation Compounds for the inhibition of histone deacetylase
CA2700841A1 (en) * 2007-09-27 2009-04-02 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
US20100305167A1 (en) * 2007-11-19 2010-12-02 Syndax Pharmaceuticals, Inc. Administration of an Inhibitor of HDAC
US20090311695A1 (en) 2008-03-12 2009-12-17 Talat Nasim Method
WO2010033658A2 (en) * 2008-09-17 2010-03-25 The Rockefeller University Cathepsin l proteolytically processes histone h3 during mouse embroyonic stem cell differentiation
US20100152204A1 (en) * 2008-12-15 2010-06-17 Jan-Gowth Chang Treatment for spinal muscular atrophy
US8211631B2 (en) * 2008-12-18 2012-07-03 Wisconsin Alumni Research Foundation In vitro model of spinal muscular atrophy
WO2010084201A1 (en) 2009-01-26 2010-07-29 Commissariat A L'energie Atomique Et Aux Energies Alternatives Novel derivative of erythromycin for the treatment and diagnosis of prion disease
US7994357B2 (en) * 2009-04-03 2011-08-09 Naturewise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
US20120077753A1 (en) * 2009-06-25 2012-03-29 Laxman Gangwani Jnk inhibitors for use in treating spinal muscular atrophy
CN102781965A (zh) * 2009-10-06 2012-11-14 安吉奥开米公司 用于转运治疗剂的组合物和方法
PL2600865T3 (pl) 2010-08-05 2019-05-31 Institut National De La Sante Et De La Rech Medicale Związek użyteczny do leczenia chorób, w których pośredniczy mutacja nonsensowna oraz kompozycje farmaceutyczne zawierające wymieniony związek
AU2011325956B2 (en) * 2010-11-12 2016-07-14 The General Hospital Corporation Polycomb-associated non-coding RNAs
CN104349676B (zh) * 2011-10-31 2017-05-31 约翰霍普金斯大学 用于治疗自闭症的方法和组合物
BR112014016287B1 (pt) * 2011-12-30 2022-08-09 F. Hoffmann - La Roche Ag Composto e composição farmacêutica
CN104203239B (zh) * 2012-01-26 2017-09-08 Ptc医疗公司 用于治疗脊髓性肌萎缩的化合物
TR201813877T4 (tr) * 2012-02-10 2018-11-21 Hoffmann La Roche Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
US9371336B2 (en) * 2012-03-01 2016-06-21 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
KR102109992B1 (ko) * 2012-03-23 2020-05-13 피티씨 테라퓨틱스, 인크. 척수성 근위축증을 치료하기 위한 화합물
US20150238483A1 (en) * 2012-09-19 2015-08-27 Centre National De La Recherche Scientifique- Cnrs Traitement des neuronopathies motrices
AU2013368805A1 (en) 2012-12-24 2015-08-13 Ramot At Tel-Aviv University Ltd. Agents for treating genetic diseases resulting from nonsense mutations, and methods for identifying the same

Also Published As

Publication number Publication date
SG11201504933WA (en) 2015-07-30
CR20150381A (es) 2015-09-09
JP2016503051A (ja) 2016-02-01
CA2894992A1 (en) 2014-07-03
WO2014102778A2 (en) 2014-07-03
BR112015015075A2 (pt) 2019-01-15
MX2015008146A (es) 2016-01-20
MD20150056A2 (ro) 2015-09-30
WO2014102778A3 (en) 2014-08-21
IL239467A0 (en) 2015-07-30
AU2013368805A1 (en) 2015-08-13
EP2934548A2 (en) 2015-10-28
KR20150098675A (ko) 2015-08-28
CL2015001814A1 (es) 2015-10-23
US20150328247A1 (en) 2015-11-19
EA201500699A1 (ru) 2015-12-30
US10987370B2 (en) 2021-04-27

Similar Documents

Publication Publication Date Title
PE20151296A1 (es) Agentes para tratar enfermedades geneticas derivadas de mutaciones sin sentido y metodos para identificarlas
CL2018000292A1 (es) Compuestos farmacéuticos
CL2018000150A1 (es) Compuestos útiles como inmunomoduladores (divisional de solicitud 201600508)
CO2017000357A2 (es) Ácidos nucleicos antisentido
MX2017002144A (es) Agentes de ácido ribonucleico (arn) de cadena doble modificados.
BR112017024929A2 (pt) conjugados de oligonucleotídeo-peptídeo
SA518400552B1 (ar) مركبات فوسفوراميدات
WO2015106128A3 (en) Rnai agents modified at the 4'-c-position
CU20170056A7 (es) Métodos para tratar infecciones por el virus filoviridae
CL2013002517A1 (es) Compuestos derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso en el tratamiento o profilaxis del cancer.
CL2014002983A1 (es) Compuestos derivados de 1h-pirazolo[3,4-b]piridina, como inhibidores de una o mas proteinas en la ruta de wnt; composicion farmaceutica que los comprende, util para el tratamiento de cancer, retinopatia diabetica, fibrosis pulmonar, artritis reumatoide, enfermedad de alzheimer, entre otras.
EA201890272A1 (ru) Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака
CR20110509A (es) Composicion farmaceutica
PE20160500A1 (es) Moduladores del factor del complemento b
UY33619A (es) Analogos de nucleotidos sustituidos
GT200600297A (es) Nuevos anticuerpos anti-madcam
MX2015012559A (es) Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson.
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
UY32937A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
BR112015025025A2 (pt) composições terapêuticas e usos das mesmas
MX2019003249A (es) Diagnostico, prevencion y tratamiento de enfermedades de la articulacion.
CL2011002766A1 (es) Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras.
CL2017003152A1 (es) Composiciones de hidroxipropil beta-ciclodextrina y métodos
WO2015168521A8 (en) P97-polynucleotide conjugates
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador

Legal Events

Date Code Title Description
FD Application declared void or lapsed